Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Nurix Therapeutics, Inc. (NRIX) had Return on Tangible Equity of -23.22% for the most recently reported fiscal quarter, ending 2025-08-31.
| Income Statement Financials | |
$7.89M |
|
$-86.42M |
|
-- |
|
$7.89M |
|
$99.28M |
|
$-91.39M |
|
$4.96M |
|
$-86.42M |
|
$-86.42M |
|
$-86.42M |
|
$-86.42M |
|
$-86.42M |
|
$-86.42M |
|
$-91.39M |
|
$-86.39M |
|
84.16M |
|
84.16M |
|
$-1.03 |
|
$-1.03 |
|
| Balance Sheet Financials | |
$440.60M |
|
$20.50M |
|
$81.87M |
|
$522.47M |
|
$82.35M |
|
-- |
|
$67.87M |
|
$150.22M |
|
$372.25M |
|
$372.25M |
|
$372.25M |
|
76.87M |
|
| Cash Flow Statement Financials | |
$-181.63M |
|
$147.51M |
|
$2.63M |
|
$110.90M |
|
$79.41M |
|
$-31.49M |
|
$28.88M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.35 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1157.65% |
|
-1157.65% |
|
-- |
|
-1094.77% |
|
-1094.77% |
|
$-190.50M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-23.22% |
|
|
Return on Tangible Equity |
-23.22% |
-16.54% |
|
-23.22% |
|
$4.84 |
|
$-2.26 |
|
$-2.16 |
|